CD4 and invasive breast carcinoma: Given the low sensitivity of immunotherapy and the heterogeneity of TME, we devised a risk score based on PLK1 expression and the infiltration of γδ T cells, eosinophils and activated CD4 T cells to predict the prognosis of BRCA patients.